ARD-101
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bariatric Surgery
Conditions
Bariatric Surgery, Obesity, Weight Gain
Trial Timeline
Mar 1, 2022 → Feb 3, 2023
NCT ID
NCT05215847About ARD-101
ARD-101 is a phase 2 stage product being developed by Aardvark Therapeutics for Bariatric Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT05215847. Target conditions include Bariatric Surgery, Obesity, Weight Gain.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07197034 | Phase 3 | Active |
| NCT05153434 | Phase 2 | Completed |
| NCT05215847 | Phase 2 | Completed |
Competing Products
9 competing products in Bariatric Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 1416 (INN imapextide) | MBX Biosciences | Phase 2 | 47 |
| MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C) | MBX Biosciences | Phase 1 | 28 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| Esomeprazole | AstraZeneca | Approved | 85 |
| Rivaroxaban 10 MG Oral Tablet [Xarelto] | Bayer | Phase 2 | 49 |
| rivaroxaban 20 mg once daily 8 days | Bayer | Phase 1 | 30 |
| Pasireotide Diaspartate | Recordati | Phase 2 | 49 |
| Avexitide | Amylyx Pharmaceuticals | Phase 3 | 72 |
| glucagon | Xeris Pharmaceuticals | Phase 1/2 | 36 |